A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: AP1189, 40 mg
DRUG: AP1189, 70 mg
DRUG: AP1189, 100 mg
DRUG: AP1189 matching placebo

Sponsor

SynAct Pharma Aps

Collaborators

[object Object]